The gene expression profiles from the HTS2 assay identified 20 hub targets, which were mapped to 84 therapeutic targets obtained from network pharmacology analysis, resulting in four key targets (AKT1, CASP8, CDK1, and CCND1) for the MGFD treatment of PCa (Figure 9A). Here, AKT1 is linked to posterior cortical atrophy.